Journal ArticleDOI
Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.
Juan Morote,Jacques Planas Morin,Anna Orsola,Jose M. Abascal,Carles Salvador,Enrique Trilla,Carles X. Raventós,Lluís Cecchini,Encabo G,Jaume Reventós +9 more
TLDR
The prevalence of osteoporosis seemed high in hormone-naive patients with prostate cancer, and it increased to more than 80% after 10 years ofADT, and clinicians should be aware of the impact of ADT on BMD to prevent bone mass loss.About:
This article is published in Urology.The article was published on 2007-03-01. It has received 165 citations till now. The article focuses on the topics: Androgen deprivation therapy & Osteoporosis.read more
Citations
More filters
Journal ArticleDOI
Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
TL;DR: ADT was associated with an increased risk of skeletal fracture, incident diabetes, and cardiovascular‐related mortality, although the absolute risk of these events was low.
Journal ArticleDOI
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Matthew R. Smith,Chris Parker,Fred Saad,Kurt Miller,Bertrand Tombal,Quan Sing Ng,Martin Boegemann,Vsevolod Matveev,Josep M. Piulats,Luis Eduardo Zucca,Oleg Karyakin,Go Kimura,Nobuaki Matsubara,William C. Nahas,Franco Nolè,Eli Rosenbaum,Axel Heidenreich,Yoshiyuki Kakehi,Amily Zhang,Heiko Krissel,Michael Teufel,Junwu Shen,Volker Wagner,Celestia S. Higano +23 more
TL;DR: Concurrent treatment with abiraterone acetate plus prednisone or prednisolone and radium-223 improves overall survival and delays the onset of symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases.
Journal ArticleDOI
Cancer treatment-induced bone loss in breast and prostate cancer.
Fred Saad,Jonathan D. Adachi,Jacques P. Brown,Leah A. Canning,Karen A. Gelmon,Robert G. Josse,Kathleen I. Pritchard +6 more
TL;DR: Adjuvant endocrine therapy with an AI or androgen deprivation can be considered a risk factor for the development of osteopenia, osteoporosis, and bone fracture, which can be mitigated by appropriate bisphosphonate therapy.
Journal ArticleDOI
Cancer-associated bone disease
René Rizzoli,Jean-Jacques Body,M. L. Brandi,Jorge B. Cannata-Andía,Daniel Chappard,A. El Maghraoui,Claus-Christian Glüer,David L. Kendler,Nicola Napoli,Alexandra Papaioannou,D. D. Pierroz,Maya Rahme,C. Van Poznak,T. J. de Villiers,G. El Hajj Fuleihan +14 more
TL;DR: The goal of this paper is to put forth an IOF position paper addressing bone diseases and cancer and summarizing the position papers of other organizations.
Journal ArticleDOI
Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer
Yu-Ning Wong,Stephen J. Freedland,Brian L. Egleston,Gary R. Hudes,J. Sanford Schwartz,Katrina Armstrong +5 more
TL;DR: Deferring immediate ADT in men with positive lymph nodes after RP may not significantly compromise survival, and these results should be validated in a prospective fashion in a similar patient population.
References
More filters
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis
L. Alexeeva,P. Burkhardt,C. Christiansen,Cyrus Cooper,Pierre D. Delmas,Olof Johnell,C. Conrad Johnston,John A. Kanis,Paul Lips,Lee J. Melton,P. Meunier,Ego Seeman,Jan J. Stepan,A. Tosteson +13 more
Journal ArticleDOI
Risk of Fracture after Androgen Deprivation for Prostate Cancer
TL;DR: Androgen-deprivation therapy for prostate cancer increases the risk of fracture and there was a statistically significant relation between the number of doses of gonadotropin-releasing hormone received during the 12 months after diagnosis and the subsequent risk of fractures.
Journal ArticleDOI
Osteoporosis in Men
TL;DR: Treatment of osteoporosis in men consists both of nonpharmacological (lifestyle factors, calcium and vitamin D supplementation) and pharmacological approaches, with efficacy similar to that seen in women.
Journal ArticleDOI
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Matthew R. Smith,Francis J. McGovern,Anthony L. Zietman,Mary Anne Fallon,Douglas Hayden,David A. Schoenfeld,Philip W. Kantoff,Joel S. Finkelstein +7 more
TL;DR: Pamidronate prevents bone loss in the hip and lumbar spine in men receiving treatment for prostate cancer with a gonadotropin-releasing hormone agonist.
Journal ArticleDOI
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Matthew R. Smith,James A. Eastham,Donald M. Gleason,Daniel Shasha,Simon Tchekmedyian,Norman Zinner +5 more
TL;DR: In this paper, a multicenter double-blind, randomized, placebo controlled clinical trial was performed to assess the effect of zoledronic acid, a potent new bisphosphonate, on bone mineral density during androgen deprivation therapy for nonmetastatic prostate cancer.